Ars Pharmaceuticals Inc (SPRY) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ars Pharmaceuticals Inc   (NASDAQ: SPRY)


Ars Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Ars Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Ars Pharmaceuticals Inc recorded a cumulative net loss of $-215 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -69.63%.

However, within the Healthcare sector 660 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4036, from total ROA ranking in the first quarter of 2026 at 4602.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -20.41 % -12.14 % -8.08 % 77.44 % 41.23 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -215 -198 -171 -80 -48
Return On Assets (TTM) -69.63 % -60.85 % -51.09 % -23.37 % -15.91 %
SPRY's Total Ranking # 4036 # 4602 # 3619 # 3469 # 3101
Total Assets (TTM) in million 249 288 328 373 313
Seq. Total Assets Change -13.24 % -12.23 % -12.11 % 18.93 % -4.23 %
Seq. Net Income Change - - - - -

SPRY's 5 Years Annual ROA >> Back to SPRY Management Effectiveness >> Compare SPRY ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 301
Sector # 661
Overall # 4082

Return On Assets Statistics
High Average Low
3.14 %
-21.97 %
-69.63 %
(Dec 31 2024)   (Jun 30 2026)



  News about Ars Pharmaceuticals Inc Return on Assets ROA

Navigating Success Neffy Nasal Spray’s Approval Amid ARS Pharmaceuticals’ Financial Hurdles,

Neffy Nasal Spray: A New Era in Pediatric Allergy Treatment Amid Financial Challenges for ARS PharmaceuticalsIn a significant advancement for pediatric medicine, ARS Pharmaceuticals recently received FDA approval for Neffy 1 mg, an innovative epinephrine nasal spray designed to combat Type I allergic reactions, including anaphylaxis, in young children weighing between 15 to less than 30 kilograms. This novel approval marks the introduction of the first and only needle-free epinephrine treatment option for this vulnerable age group, offering a less invasive and potentially more accessible response to life-threatening allergic reactions.Neffy’s approval is a critical breakthrough in the medical field, addressing the pressing need for simpler and more user-friendly emergency treatments for children who may not tolerate injections well due to fear or anxiety. The nasal spray delivery system could particularly benefit caregivers and schools by providing a straightforward, convenient method to administer life-saving medication in an emergency, a scenario that demands rapid response.



Financial Statements
Ars Pharmaceuticals Inc 's Assets $ 249 million SPRY's Balance sheet
Ars Pharmaceuticals Inc 's Income $ -62 million Quarterly SPRY's Income Statement
SPRY's Income by Division See SPRY's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -6.69 % 50.59 % -17.14 % -14.32 % -
Total Assets in million 328 351 233 281 328
Y / Y Net Income Change - - - - -
Net Income in million -171 8 -54 -35 -89
Annual Return On Assets -52.28 % 2.28 % -23.31 % -12.32 % -27.24 %

SPRY's 5 Years Annual ROA >> Back to SPRY Management Effectiveness >> Compare SPRY ROA to its Competitors



More Return On Assets Ratios
SPRY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SPRY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SPRY's Competitors
Subscribers only: Roa for Ars Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for SPRY's Customers

You may also want to know
SPRY's Roi SPRY's Inventory Turnover Ratio SPRY's Growth Rates SPRY's Dividend Comparisons
SPRY's Profitability Ratios SPRY's Asset Turnover Ratio SPRY's Dividend Growth
SPRY's Roe SPRY's Valuation Ratios SPRY's Financial Strength Ratios SPRY's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-03T12:16:46+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.